Search the Newsreel

5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call

5 Must-Read Analyst Questions From Viatris's Q2 Earnings Call Viatris' second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street's revenue and non-GAAP profit expectations. Management attributed the quarter's performance to strong commercial execution in Greater China, where investments …

Viatris Inc. stock falls Wednesday, underperforms market

Viatris Inc. (VTRS) shares fell by 1.11% on Wednesday, closing at $16.10, underperforming the broader market. The S&P 500 Index saw a gain of 0.26%, while the Dow Jones Industrial Average slightly declined by 0.04%. Viatris Inc. is now trading 12.45% below its 52-week …

Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc

Davis Selected Advisers has reported a beneficial ownership of 75,232,254 shares, representing a 6.5% stake in Viatris Inc. The firm holds sole voting power over 72,567,897 shares and sole dispositive power over all 75,232,254 shares. This disclosure, filed as a Schedule 13G/A, indicates Davis …

ETFs Investing in Viatris, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Viatris, Inc. (VTRS) stocks, sorted by market value. It details various ETFs, including their issuer, management style, focus, expense ratio, assets under management (AUM), and 3-year NAV total return. The ETFs …

Viatris Inc. (VTRS) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Viatris Inc. (VTRS) stock, including its current price, dividend information, and a collection of recent news articles. The news highlights Viatris's Q2 earnings performance, strategic moves like selling Tyrvaya, and analyst insights on its valuation …

VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook

Viatris (VTRS) reported better-than-expected Q2 CY2026 revenue and non-GAAP profit, driven by strong commercial execution in Greater China and demand for cardiovascular products. Despite this, the company faced a negative market reaction due to supply chain disruptions and lower-margin products in emerging markets. Management …

Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run

Viatris (VTRS) stock has seen a 76.1% gain over the past year, yet remains undervalued according to various valuation checks, trading at a discount to sales compared to its industry peers. The recent FDA approval for Gwyn Lo contraceptive patch and the planned sale …

Harrow adds TYRVAYA's global rights to dry eye portfolio

Harrow is expanding its dry eye product portfolio by acquiring the global rights to TYRVAYA (varenicline solution) nasal spray from Viatris, Inc. This FDA-approved nasal spray, indicated for dry eye disease, was originally developed by Oyster Point Pharma. The deal involves a $30 million …

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported its Q2 2026 financial results, including $20.7 million in revenue from its Viatris collaboration and a GAAP net loss of $5.9 million, with $387.7 million in cash and marketable securities. The company highlighted strong YUPELRI performance, a pending acquisition by Zymeworks, …

Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback

Viatris Inc. recently reported higher Q2 and year-to-date revenues, returned to net income, raised its full-year 2026 revenue guidance to US$14.75 billion, and completed a US$1.15 billion share repurchase program. Despite these positive developments, including a new FDA-approved contraceptive patch and reaffirmed dividend, the …

Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program

In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. …

Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be …

Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance …

Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress

Viatris (VTRS) has seen a modest increase in its fair value estimate to US$18.50 per share following strong Q1 results and pipeline progress, leading Barclays to lift its price target to US$22 with an Overweight rating. While analysts are optimistic about the company's execution …

Viatris (VTRS) Stock Looks Stuck Between Higher Guidance And Wider Losses

Viatris’ high-range grind stands out in a generic-drug group short on Trend Signals

VTRS finished the week at $17.56, just 2.8% below its 52-week high, with an active 49-week trend backdrop but only baseline volume confirmation.

Viatris Earnings: Good Performance in Key Regions and Outlook Increase Make for a Solid Quarter

Viatris reported a strong second quarter with 5% revenue growth and 11% adjusted earnings per share growth, both surpassing FactSet consensus estimates. The company also raised its EPS guidance by 5% at the midpoint, despite shares trading down 3% post-announcement. This performance highlights solid …

Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc.

Harrow has entered into a definitive agreement to acquire Tyrvaya (varenicline solution), a dry eye nasal spray treatment, from Viatris Inc. This acquisition aims to expand Harrow's dry eye portfolio, complementing its Vevye franchise by offering a differentiated treatment option with a distinct mechanism …

Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ...

Viatris Inc (VTRS) reported strong Q2 2026 results with $3.8 billion in revenues, a 3.5% operational growth year-over-year, and raised its full-year guidance. Key drivers included robust performance in Greater China and advancements in its R&D pipeline. The company also highlighted challenges such as …

Viatris Inc. Stock 12‑Month Price Target Raised to $18.71, Implies 6% Upside

Viatris Inc. (VTRS) has seen its average 12-month price target raised from $18.14 to $18.71 by 7 analysts, suggesting a 6% potential upside from its August 5th closing price. The consensus analyst rating remains a "Buy," with 5 out of 12 analysts recommending a …

Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued

Viatris Inc (VTRS) shares fell 7.6% to $16.29, which is still 47.7% above its GF Value of $11.03, indicating the stock is significantly overvalued. The company has a GF Score of 58/100, with weak growth potential, and recent insider selling further suggests a cautious …

Viatris Inc. stock falls Thursday, underperforms market

Viatris Inc. (VTRS) stock fell 7.71% to $16.29 on Thursday, marking its second consecutive day of losses. This decline occurred during a broader market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing losses.

Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth

Viatris, one of the largest generic drug manufacturers globally, aims for long-term growth through new product launches, pipeline progression, and cost savings. While generics face erosion in developed markets, the company plans to focus on complex generics to mitigate pricing and margin pressures. This …

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Viatris has agreed to sell its Tyrvaya nasal spray business to Harrow Inc. for up to $100 million, a move that will allow Viatris to focus on high-potential growth areas like complex generics and transdermal products, and continued investment in the Greater China market. …

Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VTRS) 2026-08-06

Viatris stock hits 52-week high at 18.27 USD

Viatris Inc. (VTRS) stock reached a 52-week high of $18.07, demonstrating strong investor confidence with a 109.7% return over the past year and a market capitalization of $20.55 billion. InvestingPro analysis suggests the stock is undervalued with a "GOOD" financial health score. Recent positive …

Form 8K Viatris Inc For: 6 August By Investing.com

This article announces that Viatris Inc. has filed a Form 8K on August 6th. The filing is presented without additional details or commentary, focusing solely on the event itself. The article also includes stock performance for VTRS and links to other related market data.

FMR LLC discloses 8.3% Viatris Inc (VTRS) ownership, over 96M shares

FMR LLC has disclosed an 8.3% beneficial ownership in Viatris Inc. (VTRS), amounting to 96,362,102.65 shares. Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same shares and stake percentage. This information comes from a SCHEDULE 13G …

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Viatris (VTRS) reported revenue of $3.76 billion, up 4.9% over the same period last year. EPS came in at $0.69, compared to $0.62 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $3.68 …

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.69 per Share, vs. FactSet Est of $0.60

Viatris Inc. (VTRS) reported Q2 adjusted EPS of $0.69 per share, surpassing the FactSet estimate of $0.60. The company also announced Q2 revenue of $3.76 billion, exceeding the FactSet estimate of $3.68 billion.

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Inc. announced strong second-quarter 2026 financial results, with total revenues of $3.8 billion, a 5% reported growth, and Adjusted EBITDA of $1.2 billion, up 8% operationally. The company raised its 2026 financial guidance midpoints, returned approximately $550 million to shareholders, and reduced its …

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 billion, …